I think the real news here is the Bristol Myers Squibb, MD Anderson Melanoma Moonshot Program that showed good numbers and can be seen as a "proof of concept" for Lag-3. My thinking is that the BMS data may derisk IMMP considerably. Those are my thoughts. Good luck to all!
Ann: TACTI-002 & INSIGHT-004 data to be presented at ASCO, page-131
Add IMM (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
31.5¢ |
Change
0.005(1.61%) |
Mkt cap ! $458.1M | |||
| Open | High | Low | Value | Volume |
| 31.0¢ | 32.0¢ | 30.8¢ | $684.8K | 2.183M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 12 | 436502 | 31.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 31.5¢ | 92443 | 1 |
View Market Depth
| Last trade - 16.10pm 12/11/2024 (20 minute delay) ? |
| IMM (ASX) Chart |